Anti-Aging Peptides

A growth hormone releasing hormone analog studied for stimulating growth hormone secretion.

A selective growth hormone secretagogue studied for targeted GH release with fewer side effects than other GH peptides.

A naturally occurring copper-binding peptide studied for skin regeneration, wound healing, and anti-aging effects.

A tetrapeptide studied for its potential to activate telomerase and influence biological aging markers.

A mitochondrial-derived peptide studied for metabolic regulation, exercise mimetic effects, and longevity.

A mitochondria-targeted peptide FDA-approved as FORZINITY (elamipretide) for Barth syndrome in September 2025 — the first FDA-approved mitochondrial-targeted therapeutic.

A hexapeptide analog studied for cognitive enhancement via hepatocyte growth factor pathway activation.

A senolytic peptide designed to selectively clear senescent cells by disrupting FOXO4-p53 interaction.

A GHRH analog FDA-approved for reducing visceral fat in HIV-associated lipodystrophy.

A GHRH analog previously FDA-approved for growth hormone deficiency diagnosis and treatment.

A long-acting GHRH analog with an extended half-life due to its Drug Affinity Complex modification.

A synthetic hexapeptide growth hormone secretagogue studied for its potent stimulation of growth hormone release via the ghrelin receptor.

A thymic peptide preparation studied for immune system rejuvenation and age-related immune decline.

A coenzyme essential for cellular energy production, studied for anti-aging and metabolic support.

A short bioregulatory peptide studied for neuroprotective effects and cognitive support in aging.

A cosmetic peptide studied for reducing the appearance of wrinkles by modulating muscle contraction signaling.

A multi-peptide blend of BPC-157, TB-500, and GHK-Cu formulated for tissue repair and skin rejuvenation.

A naturally occurring longevity hormone (secreted alpha-klotho) being studied for cognition and brain aging; a single low-dose injection improved memory in aged monkeys, and a first-in-human Phase 1 trial in older adults is underway.

An endogenous mitochondrial-derived peptide studied for neuroprotection, cellular stress resistance, and longevity, whose blood levels fall with age and are elevated in centenarians.

Abaloparatide (Tymlos) is a synthetic 34-amino-acid analog of parathyroid hormone-related protein, PTHrP(1-34), engineered to bind the PTH1 receptor with a strong preference for its transient RG conformation rather than the long-lived R0 conformation favored by teriparatide. That receptor bias produces a shorter burst of signaling per injection - enough to drive osteoblast activity, but short enough to limit the bone resorption and calcium mobilization that follow a prolonged signal. In the 18-month Phase 3 ACTIVE trial in 2,463 postmenopausal women, abaloparatide 80 mcg daily reduced new morphometric vertebral fractures by 86% versus placebo, alongside significant reductions in nonvertebral, major osteoporotic and clinical fractures. The FDA approved Tymlos in April 2017; in December 2021 the osteosarcoma boxed warning and the two-year cumulative lifetime limit were both removed from the label.